Sugi Predict

Sugi Predict / Compounds / SCHEMBL17048560

SCHEMBL17048560

SCHEMBL17048560

COc1ccc(CN(c2nncs2)S(=O)(=O)c2ccc(Oc3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)c(OC)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BMP1 P13497 3/20 0.37
▸ GAA P10253 1/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ TSHR P16473 1/20 0.35
▸ PGR P06401 2/20 0.35
▸ NR3C1 P04150 1/20 0.35
▸ SCN9A Q15858 4/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.33
▸ PTGER1 P34995 1/20 0.33
▸ CETP P11597 1/20 0.33
▸ MMP1 P03956 1/20 0.33
▸ MMP9 P14780 1/20 0.33
▸ MMP13 P45452 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18882667 0.95 SCN9A (0.37) BMP1GAAMEN1KMT2ATSHR
SCHEMBL17048608 0.88 SCN9A (0.43) SCN9A
SCHEMBL17048652 0.87 SCN9A (0.37) BMP1GAAMEN1KMT2ASCN9A
SCHEMBL17048537 0.86 BMP1 (0.39) BMP1GAAMEN1KMT2APGR
SCHEMBL17048546 0.85 MEN1 (0.40) MEN1KMT2ATSHRSCN9ANPC1
SCHEMBL17048525 0.84 SCN9A (0.43) BMP1GAAPGRNR3C1SCN9A
SCHEMBL18882673 0.84 SCN9A (0.41) SCN9A
SCHEMBL18882670 0.83 SCN9A (0.35) GAAMEN1KMT2ASCN9ANPC1
SCHEMBL17048637 0.82 SCN9A (0.38) MEN1KMT2ATSHRSCN9AMAPT
SCHEMBL18882669 0.82 GAA (0.37) BMP1GAAMEN1KMT2APGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11236078-B2 Heterocyclic inhibitors of the sodium channel DeGiacomo, Mark G. (US) 2022-02-01 — — US disclosed
US-11236078-B2 Heterocyclic inhibitors of the sodium channel DeGiacomo, Mark G. (US) 2022-02-01 — — US disclosed
US-20170145003-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL DeGiacomo, Mark G. (US) 2017-05-25 — — US disclosed
US-20170145003-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL DeGiacomo, Mark G. (US) 2017-05-25 — — US disclosed
WO-2015130957-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL Zalicus Pharmaceuticals, Ltd. (US) 2015-09-03 — — WO disclosed
WO-2015130957-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL Zalicus Pharmaceuticals, Ltd. (US) 2015-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145003-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL SCN1B, SCN1A, CACNA1S BMP1 1993/4885GAA 1797/4885MEN1 374/4885
US-11236078-B2 Heterocyclic inhibitors of the sodium channel SCN1B, TRPM6, SCN1A BMP1 2319/4885GAA 1714/4885MEN1 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.